Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System

Neurotherapeutics

Volumn 6, Issue 1, 2009, Pages 4-13

  Buccafusco, Jerry J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; attention deficit disorder; cognition; delayed responses tasks; Drug discovery; neuroprotection; working memory

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; ACETYLSALICYLIC ACID; AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBIDOPA; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; DONEPEZIL; ENTACAPONE; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; HEXAMETHONIUM; JWS USC 75 IX; JWS USC 75IX; LADOSTIGIL; LEVODOPA; LISURIDE; MECAMYLAMINE; METHYLATROPINE; MHP 133; MPH 133; NICOTINE; PHYSOSTIGMINE; PRAMIPEXOLE; RASAGILINE; RIVASTIGMINE; RS 17017; RS 56812; RS 66331; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG SAFETY; HUMAN; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; STOMACH ACID SECRETION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS;

EID: 57749105459     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.10.031     Document Type: Article

References (42)

1. Israili Z.H., Hernández-Hernández R., and Valasco M. The future of antihypertensive treatment. Am J Ther 14 (2007) 121-134
2. Korczyn A.D. Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 62 (2002) 775-786
3. Jürgen Drews Case histories, magic bullets and the state of drug discovery. Nature Rev Drug Discovery 5 (2006) 635-640
4. Kuroki T., Nagao N., and Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172 (2008) 199-212
5. Sivachenko A., Kalinin A., and Yuryev A. Pathway analysis for design of promiscuous drugs and selective drug mixtures. Curr Drug Discov Technologies 3 (2006) 269-277
6. Van Groenendael J.H., Markusse H.M., Dijkmans B.A., and Breedveld F.C. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 15 (1996) 450-456
7. Yeomans N.D., Tulassay Z., Juhász L., Rácz I., Howard J.M., van Rensburg C.J., Swannell A.J., and Hawkey C.J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
8. Davis M., Maida V., Daeninck P., and Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Supp Care Cancer 15 (2007) 63-71
9. Youdim M.B., and Weinstock M. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mechanisms Ageing Develop 123 (2002) 1081-1086
10. Sagi Y., Weinstock M., and Youdim M.B. Attenuation of MPTP-induced dopaminergic neurotoxicity by ladostigil, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 86 (2003) 290-297
11. Weinstock M., Poltyrev T., Bejar C., and Youdim M.B. Effect of ladostigil, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 160 (2002) 318-324
12. Buccafusco J.J., Terry Jr. A.V., Goren T., and Blaugrun E. Potential cognitive actions of ladostigil, a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 119 (2003) 669-678
13. Van der Schyf C.J., Gal S., Geldenhuys W.J., and Youdim M.B. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 15 (2006) 873-886
14. Yogev-Falach M., Bar-Am O., Amit T., and Youdim M.B. The multifunctional neuroprotective anti-Alzheimer/ anti-Parkinson drug ladostigil (TV3326) regulates holo-APP translation and processing. FASEB J 20 (2006) 2177-2179
15. Youdim M.B., Amit T., Bar-Am O., and Yogev-Falach M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res 10 (2006) 1-11
16. Rizzo S., Rivière C., Piazzi L., Bisi A., Gobbi S., Bartolini M., Andrisano V., Morroni F., Tarozzi A., Monti J.-P., and Rampa A. Benzofuran-based hybrid compounds for the inibition of cholinesterase activity, β amyloid aggregation, and Aβ neurotoxicity. J Med Chem 51 (2008) 2883-2886
17. Buccafusco J.J., and Terry Jr. A.V. Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J. Mol Neurosci 24 (2004) 85-91
18. Elrod K., Buccafusco J.J., and Jackson W.J. Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43 (1988) 277-287
19. Buccafusco J.J., and Jackson W.J. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12 (1991) 233-238
20. Buccafusco J.J., Prendergast M., Terry Jr. A.V., and Jackson W.J. Cognitive effects of nicotinic cholinergic agonists in non-human primates. Drug Develop Res 38 (1996) 196-203
21. Rose J.E., Westman E.C., and Behm F.M. Nicotine/mecamylamine combination treatment for smoking cessation. Drug Develop Res 38 (1996) 243-256
22. Buccafusco J.J. Neuropharmacologic and behavioral actions of clonidine: interactions with central neurotransmitters. International Rev Neurobiol 33 (1992) 55-107
23. Buccafusco J.J. Inhibition of regional brain acetylcholine biosynthesis by clonidine in spontaneously hypertensive rats. Drug Devel Res 4 (1984) 627-633
24. Buccafusco J.J., Terry Jr. A.V., Webster S.J., Martin D.M., Hohnadel E.J., Bouchard K.A., and Warner S.E. The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant conditioning memory tasks for screening drug candidates. Psychopharmacology 199 (2008) 481-494
25. Jackson W.J., and Buccafusco J.J. Clonidine enhances delayed matching-to-sample performance by young and aged monkeys. Pharmacol Biochem Behav 39 (1991) 79-84
26. Dunbar G.C., Inglis R., Kuchibhatla R., Sharma T., Tomlinson M., and Wamsley J. Effect of ispronicline, a neuronal acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 21 (2007) 171-178
27. Briggs C.A., Anderson D.J., Brioni J.D., et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21. In vitro and in vivo. Pharmacol Biochem Behav 57 (1997) 231-241
28. Buccafusco J.J., Letchworth S.R., Bencherif M., and Lippillo P.M. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacological Sci 26 (2005) 352-360
29. Buccafusco J.J., Webster S.J., Terry Jr. A.V., Kille N., and Blessing D. Protracted cognitive effects produced by clonidine in Macaca Nemestrina performing a delayed matching task. [Epub ahead of print]. Psychopharmacology (Berl) (2008) Sep 11
30. Powers J.C., Buccafusco J.J., and Starks K. Georgia Tech Research Corporation, Atlanta, GA. inventors assignee. Pyridinium Compounds (1998) US patent 5 714 615. February 3
31. Powers J.C., Buccafusco J.J., and Starks K. Georgia Tech Research Corporation, Atlanta, GA. inventors assignee. Pyridinium Compounds (1998) US patent 5 726 314. March 10
32. Buccafusco J.J., Powers J.C., Hernandez M.A., Prendergast M.A., Terry Jr. A.V., and Jonnala R.R. MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition. Neurochem Res 32 (2007) 1224-1237
33. Terry Jr. A.V., Gattu M., Buccafusco J.J., Sowell J.W., and Kosh J.W. Ranitidine analog, JWS-USC-75IX, enhances memory-related task performance in rats. Drug Dev Res 47 (1999) 97-106
34. Paule M.G., Bushnel P.J., Maurissen J.P.J., et al. Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol. Teratol 20 (1998) 493-502
35. Esbenshade T.A., Fox G.B., and Cowart M.D. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interventions 6 (2006) 77-88
36. Medhurst A.D., Atkins A.R., Beresford I.J., et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321 (2007) 1032-1045
37. Bonaventure P., Letavic M., Dugovic C., et al. Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73 (2007) 1084-1096
38. Fox G.B., Esbenshade T.A., Pan J.B., et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313 (2005) 176-190
39. Akhtar M., Uma Devi P., Ali A., Pillai K.K., and Vohora D. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Fund Clin Pharmacol 20 (2006) 373-378
40. Cassel J.C., and Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 69 (1995) 1-41
41. Terry Jr. A.V., Buccafusco J.J., and Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 16 (2008) 30-38
42. Kholdebarin E., Caldwell D.P., Blackwelder W.P., Kao M., Christopher N.C., and Levin E.D. Interaction of nicotinic and histamine H3 systems in the radial-arm maze repeated acquisition task. Eur J Pharmacol 56 (2007) 64-69